Clearmind Medicine (CMND) Competitors $1.07 +0.02 (+1.90%) Closing price 03/28/2025 03:53 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMND vs. CLDI, MTEX, CLRB, BCAB, INAB, ME, EDSA, SNTI, ELEV, and CARMShould you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include Calidi Biotherapeutics (CLDI), Mannatech (MTEX), Cellectar Biosciences (CLRB), BioAtla (BCAB), IN8bio (INAB), 23andMe (ME), Edesa Biotech (EDSA), Senti Biosciences (SNTI), Elevation Oncology (ELEV), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry. Clearmind Medicine vs. Calidi Biotherapeutics Mannatech Cellectar Biosciences BioAtla IN8bio 23andMe Edesa Biotech Senti Biosciences Elevation Oncology Carisma Therapeutics Clearmind Medicine (NASDAQ:CMND) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Does the media refer more to CMND or CLDI? In the previous week, Calidi Biotherapeutics had 2 more articles in the media than Clearmind Medicine. MarketBeat recorded 4 mentions for Calidi Biotherapeutics and 2 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 1.43 beat Calidi Biotherapeutics' score of 0.37 indicating that Clearmind Medicine is being referred to more favorably in the media. Company Overall Sentiment Clearmind Medicine Positive Calidi Biotherapeutics Neutral Is CMND or CLDI more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Clearmind MedicineN/A -129.21% -61.15% Calidi Biotherapeutics N/A N/A -344.45% Does the MarketBeat Community believe in CMND or CLDI? Clearmind Medicine and Calidi Biotherapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformClearmind MedicineN/AN/ACalidi BiotherapeuticsN/AN/A Which has more risk and volatility, CMND or CLDI? Clearmind Medicine has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Do analysts recommend CMND or CLDI? Calidi Biotherapeutics has a consensus target price of $15.00, indicating a potential upside of 2,207.69%. Given Calidi Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Calidi Biotherapeutics is more favorable than Clearmind Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in CMND or CLDI? 96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 24.3% of Calidi Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, CMND or CLDI? Clearmind Medicine has higher earnings, but lower revenue than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearmind MedicineN/AN/A-$5.26M-$1.22-0.88Calidi Biotherapeutics$50K344.03-$29.22MN/AN/A SummaryCalidi Biotherapeutics beats Clearmind Medicine on 8 of the 12 factors compared between the two stocks. Remove Ads Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMND vs. The Competition Export to ExcelMetricClearmind MedicinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.56M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.577.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book1.476.386.894.23Net Income-$5.26M$142.34M$3.20B$247.47M7 Day Performance-4.46%-5.15%-3.06%-2.29%1 Month Performance-11.57%-7.55%1.52%-5.81%1 Year Performance-6.96%-11.06%9.37%-0.96% Clearmind Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMNDClearmind Medicine0.929 of 5 stars$1.07+1.9%N/A-7.0%$4.56MN/A-0.57N/AShort Interest ↓Positive NewsCLDICalidi Biotherapeutics2.194 of 5 stars$0.70-4.2%$15.00+2,056.4%N/A$18.41M$50,000.000.0038News CoverageGap DownMTEXMannatech0.6989 of 5 stars$9.61-0.2%N/A+7.4%$18.11M$121.55M-11.86250Earnings ReportAnalyst ForecastGap UpCLRBCellectar Biosciences2.0419 of 5 stars$0.39-1.1%$17.67+4,478.0%-91.6%$17.78MN/A-0.2210Analyst ForecastShort Interest ↑BCABBioAtla2.3288 of 5 stars$0.37-0.8%$6.00+1,534.9%-89.1%$17.74M$11M-0.2260Earnings ReportShort Interest ↑News CoverageGap DownINABIN8bio3.031 of 5 stars$0.22-4.5%$6.00+2,657.4%-83.4%$17.68MN/A-0.2920Short Interest ↑ME23andMe1.2373 of 5 stars$0.65-11.0%$9.40+1,346.2%-94.3%$17.44M$208.78M-0.04770Options VolumeNews CoverageGap DownHigh Trading VolumeEDSAEdesa Biotech3.5885 of 5 stars$2.49-2.7%$21.00+743.4%-40.4%$17.41MN/A-1.3320Positive NewsSNTISenti Biosciences3.6819 of 5 stars$3.54-4.8%$10.00+182.5%-9.0%$17.10M$2.56M-0.234Short Interest ↓Positive NewsGap UpELEVElevation Oncology2.6146 of 5 stars$0.28-2.4%$3.39+1,095.9%-94.9%$16.76MN/A-0.3540High Trading VolumeCARMCarisma Therapeutics3.1013 of 5 stars$0.40+1.6%$4.94+1,134.7%-85.5%$16.70M$20.27M-0.2620News Coverage Remove Ads Related Companies and Tools Related Companies CLDI Competitors MTEX Competitors CLRB Competitors BCAB Competitors INAB Competitors ME Competitors EDSA Competitors SNTI Competitors ELEV Competitors CARM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMND) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
